ArticlePloS one2026
Impact of combined medication payment management policies on population health performance.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the mechanism and impact of a policy combination involving centralized drug procurement and national drug price negotiations on health insurance payment management and overall health performance of the population. Relying on a two-dimensional analytical framework of health outcomes and medical expenditures, the entropy value method was applied to construct indicators of residents' health portfolios. The year 2019, marked by the large-scale implementation of centralized procurement and national medicine catalog negotiations, was identified as the policy breakpoint for constructing a breakpoint regression model. Based on CFPS data, the model was implemented to evaluate changes in residents' health outcomes and medical expenditure efficiency. Furthermore, the mechanisms underlying policy effects were examined from the perspectives of drug expenditure, pharmaceutical innovation (e.g., R&D inputs and patent output), and drug trade including imports and exports. The results indicated that this policy combination significantly improved population health outcomes and enhanced the efficiency of healthcare spending. Mechanism analysis further confirmed its short-term effects on stimulating innovation, increasing drug accessibility, and promoting expenditure efficiency. In addition, empirical evidence supported the hypothesized synergy between import substitution and export upgrading. Therefore, it is recommended to establish a value-oriented drug classification and payment management mechanism while adapting regional policies to provide a scientific basis for optimizing pharmaceutical policy design and balancing health accessibility with the advancement of innovation in the pharmaceutical industry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.